Anti-CD70 antibodies: A potential treatment for EBV+ CD70-expressing lymphomas

Bruce F. Israel, Margaret Gulley, Sandra Elmore, Silvano Ferrini, Wen Hai Feng, Shannon C. Kenney

Research output: Contribution to journalArticlepeer-review


A monoclonal antibody (Rituximab) directed against the B-cell surface antigen, CD20, is increasingly used as a therapy for B-cell lymphomas. However, CD20 is expressed on all normal mature B cells and hence is not a specific tumor target. In contrast, CD70 is expressed on highly activated lymphocytes as well as on many B-cell and T-cell lymphomas but is not expressed on the great majority of B cells and T cells. In this report, we have explored the potential utility of anti-CD70 monoclonal antibodies for treatment of CD70+ EBV+ B-cell lymphomas. Using two Burkitt's lymphoma lines (Raji and Jijoye) that express surface CD70 and a CD70- Burkitt's lymphoma line (Akata), we show that two different monoclonal antibodies directed against human CD70 allow rabbit and human complement to kill EBV+ B cells in a CD70-dependent manner in vitro. In the absence of complement, neither anti-CD70 antibody induced in vitro killing of CD70+ cell lines. Importantly, i.p. injection of anti-CD70 antibodies also inhibited the growth of CD70+ Burkitt's lymphoma cells in severe combined immunodeficient mice but did not inhibit the growth of CD70- Burkitt's lymphoma cells. These results suggest that anti-CD70 antibodies may be useful for the treatment of CD70+ B-cell lymphomas.

Original languageEnglish
Pages (from-to)2037-2044
Number of pages8
JournalMolecular Cancer Therapeutics
Issue number12
Publication statusPublished - Dec 2005

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology


Dive into the research topics of 'Anti-CD70 antibodies: A potential treatment for EBV+ CD70-expressing lymphomas'. Together they form a unique fingerprint.

Cite this